United States Patent 7,834,060: Adapalene 0.3% Gel Patent Scope, Expiration and Generic Risk

US Patent No. 7,834,060 is a formulation-and-method patent directed to topical acne treatment using 0.3% adapalene, particularly a gel containing carbomer 940, disodium edetate, methylparaben, poloxamer 124, propylene glycol, sodium hydroxide and purified water. The patent does not broadly control all adapalene products. Its strongest commercial relevance is to 0.3% adapalene gel products that materially match the claimed concentration, excipient architecture and acne-treatment methods.

The patent issued Nov. 16, 2010, and is associated with Galderma's Differin Gel 0.3% product. Public patent-term and Orange Book records identify a September 2026 expiration date, subject to any applicable patent-term adjustment or regulatory modification. The patent's principal vulnerability is claim breadth: many claims cover a defined concentration and therapeutic use but do not require the complete commercial formulation. A generic applicant may therefore attempt a Paragraph IV strategy based on noninfringement, invalidity, or both.

What does US Patent 7,834,060 cover?

The patent covers methods and regimens for treating acne by topically administering a pharmaceutical composition containing 0.3% adapalene. The covered conditions include:

Common acne
Comedones
Polymorphous acne
Nodulocystic acne
Acne conglobata
Secondary acne

The claims are method claims, not composition claims standing alone. Infringement generally requires both use of a qualifying composition and performance of the claimed topical acne-treatment method.

The patent has four principal claim groups:

Claim group	Core subject matter	Key limitation
Claims 1-3	Treatment method using 0.3% adapalene in a gel or cream	Specified excipient Markush group and water
Claims 4-5	Treatment method using a defined 0.3% adapalene gel	Specific eight-component formulation
Claims 6-11	Treatment regimen using 0.3% adapalene	Broader excipient group and gel limitation in dependent claims
Claims 12-35	“Consisting essentially of” method and regimen claims	Repeated formulation, disease and gel limitations

Claims 23-33 are commercially important because they recite 0.3% adapalene as the sole active anti-acne agent in a pharmaceutically acceptable vehicle. Claims 34 and 35 recite the specific gel formulation and common-acne treatment.

How should the “consisting essentially of” language be interpreted?

The phrase “consisting essentially of” narrows the claims to compositions containing the recited ingredients and excludes additional ingredients that materially affect the basic and novel characteristics of the invention.

The practical effect is claim-dependent:

An accused product may include ordinary excipients not expressly listed if those excipients do not materially alter the claimed formulation characteristics.
An additional active pharmaceutical ingredient may create a substantial noninfringement position, particularly under claims requiring adapalene as the sole active anti-acne agent.
The phrase does not automatically require an exact commercial recipe unless the claim expressly recites the individual ingredients.
Claims 4, 15, 26, 27 and 34 are narrower because they identify a particular excipient set.
Claims 1, 6, 12 and 17 are broader in ingredient selection because they use Markush groups.

A court would construe “consisting essentially of” in view of the specification, prosecution history and the characteristics identified as essential to the invention. The phrase does not eliminate the need to prove every express limitation.

What are the strongest claims in US 7,834,060?

The strongest literal infringement targets are the claims directed to the exact 0.3% gel formulation.

Exact-formulation claims

Claims 4 and 34 require a gel consisting of:

0.3% adapalene
Carbomer 940
Disodium edetate
Methylparaben
Poloxamer 124
Propylene glycol
Sodium hydroxide
Purified water

Claims 15, 26 and 27 repeat or narrow this formulation through dependent-claim structure. These claims are potentially powerful against a product that uses the same concentration and substantially the same excipient system.

Their weakness is factual specificity. A generic manufacturer can seek to avoid literal infringement by changing one or more formulation elements, such as:

Replacing carbomer 940 with another carbomer
Using a different chelating agent
Omitting methylparaben
Substituting a different surfactant or emulsifier
Using a different pH adjuster
Employing a nonaqueous or materially different vehicle

Whether a substitution avoids infringement depends on the claim language, equivalence arguments and prosecution history.

Markush-formulation claims

Claims 1 and 12 cover 0.3% adapalene in a gel or cream containing water and one or more selected excipients, including carbomer 940, carbomer 934, propylene glycol, perhydrosqualene, cyclomethicone, PEG-20 methyl glucose sesquistearate and methyl glucose sesquistearate.

These claims have broader formulation coverage than the exact-gel claims. They can reach products that do not copy the full Differin 0.3% formula but use one or more listed excipients.

Sole-active claims

Claims 23-33 cover a gel or cream containing 0.3% adapalene as the sole active anti-acne agent in a pharmaceutically acceptable medium. These claims have significant commercial reach because they are less dependent on a particular excipient combination.

Their principal limitations are:

The adapalene concentration must be 0.3% by weight.
Adapalene must be the sole active anti-acne agent.
The product must be used topically for one of the recited acne conditions.
The composition must be a gel or cream under the applicable claims.

A combination product containing benzoyl peroxide, clindamycin, or another active may fall outside the sole-active limitations, although other claims or patents may apply.

Which claims cover Differin Gel 0.3%?

Differin Gel 0.3% is the clearest commercial product associated with the patent. FDA labeling identifies adapalene 0.3% as the active ingredient and lists a gel formulation containing carbomer 940, disodium edetate, methylparaben, poloxamer 124, propylene glycol, sodium hydroxide and purified water.[2]

That formulation maps closely to claims 4, 15, 26, 27 and 34. The product also implicates the broader claims covering:

0.3% adapalene
Topical treatment of common acne
Gel dosage form
Adapalene as the sole active anti-acne agent
A pharmaceutically acceptable vehicle

The commercial product therefore presents multiple overlapping claim theories. A successful design-around of the exact formulation claims may not avoid the broader sole-active or Markush claims.

What is the expiration date of US Patent 7,834,060?

The publicly reported patent expiration date is September 14, 2026. The patent was issued Nov. 16, 2010. The applicable term is generally measured from the earliest effective nonprovisional filing date for the relevant patent family, subject to patent-term adjustment under 35 U.S.C. § 154 and any terminal disclaimer.

Event	Date or status
Patent issued	Nov. 16, 2010
Patent number	US 7,834,060 B2
Technology	0.3% topical adapalene formulations and acne treatment
Reference product	Differin Gel 0.3%
Reported patent expiration	Sept. 14, 2026
Regulatory pathway	NDA product with ANDA substitution potential
Post-expiration risk	Generic entry, subject to other valid patents or regulatory requirements

The patent's expiration does not automatically establish immediate market entry. A generic applicant may enter earlier if it prevails in Paragraph IV litigation, receives a covenant or license, reaches a settlement permitting launch, or otherwise satisfies the Hatch-Waxman framework.

What is the Orange Book status of adapalene 0.3%?

The FDA Orange Book is the controlling public source for listed patents and regulatory exclusivity associated with approved drug products. Differin Gel 0.3% is an FDA-approved topical adapalene product marketed by Galderma.[1]

The patent is relevant to the Orange Book because its claims describe the approved 0.3% gel's formulation and method of use. The commercial consequences are:

An ANDA applicant must address listed patents through a Paragraph I, II, III or IV certification.
A Paragraph IV certification can trigger patent litigation under 21 U.S.C. § 355(j)(5)(B)(iii).
A timely patent-infringement suit may create a 30-month stay of final ANDA approval, subject to statutory exceptions.
Expiration or delisting of the relevant patent removes that specific Orange Book barrier but does not eliminate non-Orange-Book patent exposure.

FDA approval of an ANDA does not adjudicate patent validity. The FDA evaluates pharmaceutical equivalence, bioequivalence, manufacturing and labeling requirements, not whether the listed patent is valid or infringed.

When did adapalene 0.3% lose regulatory exclusivity?

Adapalene is an established retinoid, and the 0.3% gel was approved as a new strength or formulation rather than as a new molecular entity. Any associated three-year FDA exclusivity would have expired before the patent term.

The principal commercial barrier has therefore been patent protection rather than continuing statutory data exclusivity. FDA exclusivity and patent protection are separate:

Protection	Function	Relevance to 0.3% adapalene
NCE exclusivity	Blocks certain ANDA submissions for five years	Not the principal protection for an established adapalene molecule
Three-year exclusivity	Protects approved clinical investigation for a new formulation, indication or strength	Limited period following approval
Orange Book patent	Requires patent certification and can trigger litigation	Main remaining barrier before patent expiry
Pediatric exclusivity	Adds six months when statutory requirements are met	Must be confirmed from the specific FDA record

Which companies have challenged or competed with Differin 0.3%?

The competitive field includes generic adapalene manufacturers and branded topical-retinoid suppliers. Publicly reported generic activity has involved companies seeking approval for adapalene gel products, including Taro and other ANDA sponsors. The exact litigation posture must be assessed from the FDA Orange Book, ANDA litigation docket and current FDA approval records because ANDA ownership, transfer and settlement status can change.

The relevant competitive products include:

Product or class	Active ingredient	Relationship to US 7,834,060
Differin Gel 0.3%	Adapalene 0.3%	Primary reference product and closest claim target
Generic adapalene 0.3% gel	Adapalene 0.3%	Direct ANDA competition
Differin 0.1% products	Adapalene 0.1%	Outside the 0.3% concentration limitation
Tretinoin products	Tretinoin	Different active ingredient
Tazarotene products	Tazarotene	Different retinoid and patent estate
Trifarotene products	Trifarotene	Different retinoid and newer patent estate
Adapalene/benzoyl peroxide	Two active agents	Potentially outside sole-active claims

The patent does not cover all acne treatments or all topical retinoids. It is concentrated around 0.3% adapalene and specific topical vehicles.

What Paragraph IV challenges and litigation risks exist?

A Paragraph IV applicant could challenge US 7,834,060 on several grounds.

Noninfringement

The applicant could argue that its product does not satisfy one or more limitations, including:

Concentration is not 0.3% by weight
Adapalene is not the sole active anti-acne agent
The product is not a gel or cream
The formulation lacks a required listed excipient
The proposed labeling does not induce the patented acne-treatment use
The product uses a materially different vehicle

This is the most commercially practical challenge where the generic formulation differs from the listed Differin formulation.

Invalidity

Potential invalidity theories include:

Anticipation under 35 U.S.C. § 102
Obviousness under 35 U.S.C. § 103
Lack of written description or enablement under § 112
Indefiniteness under § 112
Double patenting
Improper claim scope arising from prosecution amendments

The prior-art challenge would focus on earlier adapalene compositions, known 0.1% and 0.3% retinoid formulations, acne-treatment methods and routine excipient substitutions. The exact combination of concentration, vehicle, formulation stability and clinical use would determine obviousness strength.

Induced infringement

Because the claims are method claims, the approved label is central. If a generic label directs use of 0.3% adapalene for common acne, the label may provide evidence supporting induced infringement. A label carve-out can reduce risk only if the omitted use is legally separable and the remaining labeling does not still encourage the patented method.

How strong is the patent estate for 0.3% adapalene?

The estate is moderately strong against a direct copy of Differin Gel 0.3%, but less comprehensive against redesigned formulations.

Factor	Assessment
Product relevance	High; the claims closely track the 0.3% gel
Concentration limitation	Clear and commercially important
Exact formulation claims	Strong against direct formula duplication
Broader sole-active claims	Wider reach but greater construction risk
Method-of-use coverage	Strong for common-acne labeling using 0.3% adapalene
Coverage of combination products	Limited where claims require sole active
Coverage of 0.1% adapalene	None under the 0.3% claims
Manufacturing-process coverage	Not apparent from the supplied claims
Device or package coverage	Not apparent from the supplied claims
Biosimilar relevance	None; adapalene is a small molecule
Design-around potential	Material through concentration, excipient and active-ingredient changes

The patent is not a biologic patent and does not create biosimilar risk. The relevant competitors are ANDA-based generic manufacturers, not biosimilar applicants.

What manufacturing and formulation barriers remain after patent expiry?

After patent expiry, the principal barriers shift from patent exclusivity to pharmaceutical development and regulatory execution. A generic sponsor must establish:

Pharmaceutical equivalence
Appropriate adapalene assay and impurity controls
Gel viscosity and rheology
Content uniformity
Stability
Microbiological quality
Preservative performance, where applicable
Container-closure compatibility
Bioequivalence under the FDA's topical-product framework
Commercial-scale manufacturing reproducibility

A formulation that avoids claim 34 may still need substantial development work to match the reference product's performance. Those technical requirements are regulatory barriers, not necessarily patent barriers.

What licensing and settlement issues affect entry?

A patent settlement can establish a licensed early-entry date, supply arrangement, authorized-generic structure or other commercial terms. A settlement does not necessarily eliminate the patent or establish validity. It allocates launch timing and litigation risk between the parties.

No licensing right should be inferred merely from FDA approval, an Orange Book listing or a generic product's market presence. Entry rights depend on the applicable settlement, license, covenant not to sue, patent expiry and regulatory approval status.

What geographic coverage does US 7,834,060 provide?

US 7,834,060 provides rights only in the United States. It does not directly control sales, manufacturing or use in Canada, Europe, Japan or other jurisdictions.

International protection must be analyzed through corresponding national patents and regional filings. A company may face:

Different expiration dates
Different claim scope
Patent invalidation in one country but not another
Separate formulation or method patents
Distinct settlement agreements
Different regulatory exclusivity periods

US freedom-to-operate analysis therefore cannot be exported automatically to foreign markets.

Key Takeaways

US 7,834,060 is centered on topical 0.3% adapalene for acne treatment.
Claims 4, 15, 26, 27 and 34 are the most formulation-specific and most directly aligned with Differin Gel 0.3%.
Claims 23-33 provide broader coverage for 0.3% adapalene as the sole active anti-acne agent.
The reported patent expiration date is Sept. 14, 2026.
The patent is a small-molecule formulation and method patent, not a biologic or biosimilar patent.
A generic applicant's main strategies are formulation design-around, Paragraph IV invalidity, noninfringement, label carve-out or negotiated early entry.
The patent does not cover 0.1% adapalene, all topical retinoids, or all adapalene combination products.
Exact current litigation, settlement and ANDA status must be read from the active FDA and court records tied to each applicant and product.

FAQs

Does US 7,834,060 cover over-the-counter adapalene 0.1%?

No. The asserted claims supplied here require 0.3% adapalene by weight. A 0.1% adapalene product does not meet that concentration limitation.

Can a generic use adapalene 0.3% with a different gel base?

Potentially. A different gel base may avoid the exact-formulation claims, but the product could still implicate broader Markush or sole-active claims depending on its excipients and labeling.

Does adding benzoyl peroxide avoid all claims in US 7,834,060?

No. It may create a defense to claims requiring adapalene as the sole active anti-acne agent. It would not automatically avoid claims that do not contain that limitation, and separate combination-product patents may apply.

Is US 7,834,060 a composition patent or a method patent?

The supplied claims are method and regimen claims. They require topical administration for treatment of specified acne conditions. The patent does not, based on these claims alone, provide a standalone composition claim against making or selling the formulation without the claimed treatment use.

Does patent expiration guarantee immediate generic launch?

No. Launch also depends on FDA approval, any remaining Orange Book patents, litigation outcomes, settlement restrictions, manufacturing readiness and applicable regulatory requirements.

References

U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
U.S. Food and Drug Administration. (n.d.). Differin Gel 0.3% prescribing information. https://www.accessdata.fda.gov/
United States Patent and Trademark Office. (2010). U.S. Patent No. 7,834,060, topical adapalene compositions and methods of treatment. https://patents.google.com/patent/US7834060B2
U.S. Food and Drug Administration. (n.d.). Approved drug product labels and regulatory information for adapalene products. https://www.accessdata.fda.gov/scripts/cder/daf/
United States Code, 35 U.S.C. §§ 102, 103, 112, 154. (2024). Patentability, specification requirements and patent term. https://uscode.house.gov/
United States Code, 21 U.S.C. § 355. (2024). New drug applications and abbreviated new drug applications. https://uscode.house.gov/

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
France	02 03070	Mar 12, 2002

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	038924	⤷ Start Trial
Austria	417610	⤷ Start Trial
Austria	432072	⤷ Start Trial
Australia	2003216898	⤷ Start Trial
Australia	2008203279	⤷ Start Trial
Brazil	0307550	⤷ Start Trial
Brazil	PI0307550	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 7,834,060

Summary for Patent: 7,834,060